|
1
|
Estey EH: Acute myeloid leukemia: 2013
update on risk-stratification and management. Am J Hematol.
88:318–327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dombret H and Gardin C: An update of
current treatments for adult acute myeloid leukemia. Blood.
127:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khalaj M, Tavakkoli M, Stranahan AW and
Park CY: Pathogenic microRNA's in myeloid malignancies. Front
Genet. 5:3612014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marcucci G, Haferlach T and Döhner H:
Molecular genetics of adult acute myeloid leukemia: Prognostic and
therapeutic implications. J Clin Oncol. 29:475–486. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Estey E and Döhner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baldus CD, Mrózek K, Marcucci G and
Bloomfield CD: Clinical outcome of de novo acute myeloid leukaemia
patients with normal cytogenetics is affected by molecular genetic
alterations: A concise review. Br J Haematol. 137:387–400. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bi L, Zhou B, Li H, He L, Wang C, Wang Z,
Zhu L, Chen M and Gao S: A novel miR-375-HOXB3-CDCA3/DNMT3B
regulatory circuitry contributes to leukemogenesis in acute myeloid
leukemia. BMC Cancer. 18:1822018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang TJ, Lin J, Zhou JD, Li XX, Zhang W,
Guo H, Xu ZJ, Yan Y, Ma JC and Qian J: High bone marrow miR-19b
level predicts poor prognosis and disease recurrence in de novo
acute myeloid leukemia. Gene. 640:79–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang S, Zhang Q, Shi G and Yin J:
MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid
leukemia as a potential therapeutic target. Biomed Pharmacother.
97:1189–1194. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zebisch A, Hatzl S, Pichler M, Wölfler A
and Sill H: Therapeutic resistance in acute myeloid leukemia: The
role of non-coding RNAs. Int J Mol Sci. 17(pii): E20802016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan N, Zhang J, Cheng C, Zhang X, Feng J
and Kong R: MicroRNA-384 represses the growth and invasion of
non-small-cell lung cancer by targeting astrocyte elevated
gene-1/Wnt signaling. Biomed Pharmacother. 95:1331–1337. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Xue J, Kuang H, Zhou X, Liao L and
Yin F: microRNA-1297 inhibits the growth and metastasis of
colorectal cancer by suppressing cyclin D2 expression. DNA Cell
Biol. 36:991–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
You Y, Tan J, Gong Y, Dai H, Chen H, Xu X,
Yang A, Zhang Y and Bie P: MicroRNA-216b-5p Functions as a
Tumor-suppressive RNA by targeting TPT1 in pancreatic cancer cells.
J Cancer. 8:2854–2865. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma QL, Wang JH, Yang M, Wang HP and Jin J:
MiR-362-5p as a novel prognostic predictor of cytogenetically
normal acute myeloid leukemia. J Transl Med. 16:682018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang Y, Zou Y, Lin L, Ma X and Chen H:
Identification of serum miR-34a as a potential biomarker in acute
myeloid leukemia. Cancer Biomark. 22:799–805. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding C, Chen SN, Macleod RAF, Drexler HG,
Nagel S, Wu DP, Sun AN and Dai HP: MiR-130a is aberrantly
overexpressed in adult acute myeloid leukemia with t(8;21) and its
suppression induces AML cell death. Ups J Med Sci. 123:19–27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao Q, Li J, Chen S, Shen K, Ai G, Dai X,
Xie B, Shi Y, Jiang S, Feng J and Li W: Decreased miR-144
expression as a non-invasive biomarker for acute myeloid leukemia
patients. Pharmazie. 72:232–235. 2017.PubMed/NCBI
|
|
18
|
Wu Z, Hu Z, Han X, Li Z, Zhu Q, Wang Y,
Zheng Q and Yan J: The BET-Bromodomain Inhibitor JQ1 synergized
ABT-263 against colorectal cancer cells through suppressing
c-Myc-induced miR-1271-5p expression. Biomed Pharmacother.
95:1574–1579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin MF, Yang YF, Peng ZP, Zhang MF, Liang
JY, Chen W, Liu XH and Zheng YL: FOXK2, regulted by miR-1271-5p,
promotes cell growth and indicates unfavorable prognosis in
hepatocellular carcinoma. Int J Biochem Cell Biol. 88:155–161.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Li J, Hu J, Zheng J, Zheng Z, Liu
T, Lin Z and Lin M: Emodin enhances ATRA-induced differentiation
and induces apoptosis in acute myeloid leukemia cells. Int J Oncol.
45:2076–2084. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liao Q, Wang B, Li X and Jiang G: miRNAs
in acute myeloid leukemia. Oncotarget. 8:3666–3682. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tian C, Zheng G, Zhuang H, Li X, Hu D, Zhu
L, Wang T, You MJ and Zhang Y: MicroRNA-494 activation suppresses
bone marrow stromal cell-mediated drug resistance in acute myeloid
leukemia cells. J Cell Physiol. 232:1387–1395. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang DQ, Zhou JD, Wang YX, Deng ZQ, Yang
J, Yao DM, Qian Z, Yang L, Lin J and Qian J: Low miR-34c expression
is associated with poor outcome in de novo acute myeloid leukemia.
Int J Lab Hematol. 39:42–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang X, Hu C, Arnovitz S, Bugno J, Yu M,
Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, et al: miR-22 has a
potent anti-tumour role with therapeutic potential in acute myeloid
leukaemia. Nat Commun. 7:114522016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Inaguma S, Ito H, Riku M, Ikeda H and
Kasai K: Addiction of pancreatic cancer cells to zinc-finger
transcription factor ZIC2. Oncotarget. 6:28257–28268. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu SX, Zhang CZ, Luo RZ, Wang CH, Liu LL,
Fu J, Zhang L, Wang H, Xie D and Yun JP: Zic2 promotes tumor growth
and metastasis via PAK4 in hepatocellular carcinoma. Cancer Lett.
402:71–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marchini S, Poynor E, Barakat RR, Clivio
L, Cinquini M, Fruscio R, Porcu L, Bussani C, D'Incalci M, Erba E,
et al: The zinc finger gene ZIC2 has features of an oncogene and
its overexpression correlates strongly with the clinical course of
epithelial ovarian cancer. Clin Cancer Res. 18:4313–4324. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sakuma K, Kasamatsu A, Yamatoji M, Yamano
Y, Fushimi K, Iyoda M, Ogoshi K, Shinozuka K, Ogawara K, Shiiba M,
et al: Expression status of Zic family member 2 as a prognostic
marker for oral squamous cell carcinoma. J Cancer Res Clin Oncol.
136:553–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chan DW, Liu VW, Leung LY, Yao KM, Chan
KK, Cheung AN and Ngan HY: Zic2 synergistically enhances Hedgehog
signalling through nuclear retention of Gli1 in cervical cancer
cells. J Pathol. 225:525–534. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen ZH, Zhao KM and Du T: HOXA10 promotes
nasopharyngeal carcinoma cell proliferation and invasion via
inducing the expression of ZIC2. Eur Rev Med Pharmacol Sci.
21:945–952. 2017.PubMed/NCBI
|
|
32
|
Zhu P, Wang Y, He L, Huang G, Du Y, Zhang
G, Yan X, Xia P, Ye B, Wang S, et al: ZIC2-dependent OCT4
activation drives self-renewal of human liver cancer stem cells. J
Clin Invest. 125:3795–3808. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Ma W and Liu Y: Long non-coding
RNA HULC promotes bladder cancer cells proliferation but inhibits
apoptosis via regulation of ZIC2 and PI3K/AKT signaling pathway.
Cancer Biomark. 20:425–434. 2017. View Article : Google Scholar : PubMed/NCBI
|
